Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system
The present study was performed both to investigate whether there might be a difference between the selective serotonin re-uptake inhibitors, (SSRIs) with regard to the incidence of withdrawal reactions, and to describe the associated symptoms. From the WHO database, therefore, all case reports from...
Gespeichert in:
| Veröffentlicht in: | European journal of clinical pharmacology 1997, Vol.53 (3-4), p.163-169 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 169 |
|---|---|
| container_issue | 3-4 |
| container_start_page | 163 |
| container_title | European journal of clinical pharmacology |
| container_volume | 53 |
| creator | STAHL, M. M. S LINDQUIST, M PETTERSSON, M EDWARDS, I. R SANDERSON, J. H TAYLOR, N. F. A FLETCHER, A. P SCHOU, J. S |
| description | The present study was performed both to investigate whether there might be a difference between the selective serotonin re-uptake inhibitors, (SSRIs) with regard to the incidence of withdrawal reactions, and to describe the associated symptoms. From the WHO database, therefore, all case reports from the year of introduction for each of the SSRIs, fluoxetine, paroxetine and sertraline, were retrieved. Sales figures were obtained from Intercontinental Medical Statistics International. The reporting rates were calculated as the number of reports per million defined daily doses (DDDs) sold per year.
The reporting rate of withdrawal reactions for paroxetine was found to be higher than that for sertraline and fluoxetine in each of the countries selected for detailed analyses (US, UK and Australia), as well as for all 16 countries combined. Moreover, using the WHO system of organ classification, the ratio of central nervous system to psychiatric withdrawal symptoms was 1.9 and 2.1 for paroxetine and sertraline, respectively, whereas that for fluoxetine was 0.48, indicating a possible qualitative difference between the SSRIs with respect to the nature of the withdrawal syndrome. |
| doi_str_mv | 10.1007/s002280050357 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1530424151</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3319868101</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-4539d370dea6fb9bd8f5347ea71cc0afef3d7b8f7dc9def2f8fb7f50a67931c93</originalsourceid><addsrcrecordid>eNpVkM1LAzEQxYMotVaPHoWAXlcnm82mOUpRKxR6UXpcs_mgW9vNmmQt_e-NdBE8zcx7P97AQ-iawD0B4A8BIM-nAAwo4ydoTAqaZwQKcorGAJRkpeBwji5C2AAQJoCO0EgUvIS8HKOPVRPX2su93GJvpIqNawPeJxEHszXp_jZp8y66tmkTkvVdlJ8GN-26qZvofMAyJL1zPhqNo8NxbfBqvsThEKLZXaIzK7fBXA1zgt6fn95m82yxfHmdPS4yRQsWs4JRoSkHbWRpa1HrqWW04EZyohRIayzVvJ5arpXQxuZ2amtuGciSC0qUoBN0e8ztvPvqTYjVxvW-TS8rwigUeUEYSVR2pJR3IXhjq843O-kPFYHqt87qX52JvxlS-3pn9B899Jf8u8GXQcmt9bJVTfjDcgIlEYT-AAKOffQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1530424151</pqid></control><display><type>article</type><title>Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>STAHL, M. M. S ; LINDQUIST, M ; PETTERSSON, M ; EDWARDS, I. R ; SANDERSON, J. H ; TAYLOR, N. F. A ; FLETCHER, A. P ; SCHOU, J. S</creator><creatorcontrib>STAHL, M. M. S ; LINDQUIST, M ; PETTERSSON, M ; EDWARDS, I. R ; SANDERSON, J. H ; TAYLOR, N. F. A ; FLETCHER, A. P ; SCHOU, J. S</creatorcontrib><description>The present study was performed both to investigate whether there might be a difference between the selective serotonin re-uptake inhibitors, (SSRIs) with regard to the incidence of withdrawal reactions, and to describe the associated symptoms. From the WHO database, therefore, all case reports from the year of introduction for each of the SSRIs, fluoxetine, paroxetine and sertraline, were retrieved. Sales figures were obtained from Intercontinental Medical Statistics International. The reporting rates were calculated as the number of reports per million defined daily doses (DDDs) sold per year.
The reporting rate of withdrawal reactions for paroxetine was found to be higher than that for sertraline and fluoxetine in each of the countries selected for detailed analyses (US, UK and Australia), as well as for all 16 countries combined. Moreover, using the WHO system of organ classification, the ratio of central nervous system to psychiatric withdrawal symptoms was 1.9 and 2.1 for paroxetine and sertraline, respectively, whereas that for fluoxetine was 0.48, indicating a possible qualitative difference between the SSRIs with respect to the nature of the withdrawal syndrome.</description><identifier>ISSN: 0031-6970</identifier><identifier>EISSN: 1432-1041</identifier><identifier>DOI: 10.1007/s002280050357</identifier><identifier>PMID: 9476026</identifier><language>eng</language><publisher>Heidelberg: Springer</publisher><subject>1-Naphthylamine - adverse effects ; 1-Naphthylamine - analogs & derivatives ; Adverse Drug Reaction Reporting Systems ; Antidepressants ; Biological and medical sciences ; Drug toxicity and drugs side effects treatment ; Female ; Fluoxetine - adverse effects ; Humans ; Male ; Medical sciences ; Paroxetine - adverse effects ; Pharmacology. Drug treatments ; Serotonin Uptake Inhibitors - adverse effects ; Sertraline ; Substance Withdrawal Syndrome ; Toxicity: nervous system and muscle ; World Health Organization</subject><ispartof>European journal of clinical pharmacology, 1997, Vol.53 (3-4), p.163-169</ispartof><rights>1998 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 1997</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c345t-4539d370dea6fb9bd8f5347ea71cc0afef3d7b8f7dc9def2f8fb7f50a67931c93</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2106191$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9476026$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>STAHL, M. M. S</creatorcontrib><creatorcontrib>LINDQUIST, M</creatorcontrib><creatorcontrib>PETTERSSON, M</creatorcontrib><creatorcontrib>EDWARDS, I. R</creatorcontrib><creatorcontrib>SANDERSON, J. H</creatorcontrib><creatorcontrib>TAYLOR, N. F. A</creatorcontrib><creatorcontrib>FLETCHER, A. P</creatorcontrib><creatorcontrib>SCHOU, J. S</creatorcontrib><title>Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system</title><title>European journal of clinical pharmacology</title><addtitle>Eur J Clin Pharmacol</addtitle><description>The present study was performed both to investigate whether there might be a difference between the selective serotonin re-uptake inhibitors, (SSRIs) with regard to the incidence of withdrawal reactions, and to describe the associated symptoms. From the WHO database, therefore, all case reports from the year of introduction for each of the SSRIs, fluoxetine, paroxetine and sertraline, were retrieved. Sales figures were obtained from Intercontinental Medical Statistics International. The reporting rates were calculated as the number of reports per million defined daily doses (DDDs) sold per year.
The reporting rate of withdrawal reactions for paroxetine was found to be higher than that for sertraline and fluoxetine in each of the countries selected for detailed analyses (US, UK and Australia), as well as for all 16 countries combined. Moreover, using the WHO system of organ classification, the ratio of central nervous system to psychiatric withdrawal symptoms was 1.9 and 2.1 for paroxetine and sertraline, respectively, whereas that for fluoxetine was 0.48, indicating a possible qualitative difference between the SSRIs with respect to the nature of the withdrawal syndrome.</description><subject>1-Naphthylamine - adverse effects</subject><subject>1-Naphthylamine - analogs & derivatives</subject><subject>Adverse Drug Reaction Reporting Systems</subject><subject>Antidepressants</subject><subject>Biological and medical sciences</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Female</subject><subject>Fluoxetine - adverse effects</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Paroxetine - adverse effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Serotonin Uptake Inhibitors - adverse effects</subject><subject>Sertraline</subject><subject>Substance Withdrawal Syndrome</subject><subject>Toxicity: nervous system and muscle</subject><subject>World Health Organization</subject><issn>0031-6970</issn><issn>1432-1041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpVkM1LAzEQxYMotVaPHoWAXlcnm82mOUpRKxR6UXpcs_mgW9vNmmQt_e-NdBE8zcx7P97AQ-iawD0B4A8BIM-nAAwo4ydoTAqaZwQKcorGAJRkpeBwji5C2AAQJoCO0EgUvIS8HKOPVRPX2su93GJvpIqNawPeJxEHszXp_jZp8y66tmkTkvVdlJ8GN-26qZvofMAyJL1zPhqNo8NxbfBqvsThEKLZXaIzK7fBXA1zgt6fn95m82yxfHmdPS4yRQsWs4JRoSkHbWRpa1HrqWW04EZyohRIayzVvJ5arpXQxuZ2amtuGciSC0qUoBN0e8ztvPvqTYjVxvW-TS8rwigUeUEYSVR2pJR3IXhjq843O-kPFYHqt87qX52JvxlS-3pn9B899Jf8u8GXQcmt9bJVTfjDcgIlEYT-AAKOffQ</recordid><startdate>1997</startdate><enddate>1997</enddate><creator>STAHL, M. M. S</creator><creator>LINDQUIST, M</creator><creator>PETTERSSON, M</creator><creator>EDWARDS, I. R</creator><creator>SANDERSON, J. H</creator><creator>TAYLOR, N. F. A</creator><creator>FLETCHER, A. P</creator><creator>SCHOU, J. S</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>1997</creationdate><title>Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system</title><author>STAHL, M. M. S ; LINDQUIST, M ; PETTERSSON, M ; EDWARDS, I. R ; SANDERSON, J. H ; TAYLOR, N. F. A ; FLETCHER, A. P ; SCHOU, J. S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-4539d370dea6fb9bd8f5347ea71cc0afef3d7b8f7dc9def2f8fb7f50a67931c93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>1-Naphthylamine - adverse effects</topic><topic>1-Naphthylamine - analogs & derivatives</topic><topic>Adverse Drug Reaction Reporting Systems</topic><topic>Antidepressants</topic><topic>Biological and medical sciences</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Female</topic><topic>Fluoxetine - adverse effects</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Paroxetine - adverse effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Serotonin Uptake Inhibitors - adverse effects</topic><topic>Sertraline</topic><topic>Substance Withdrawal Syndrome</topic><topic>Toxicity: nervous system and muscle</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>STAHL, M. M. S</creatorcontrib><creatorcontrib>LINDQUIST, M</creatorcontrib><creatorcontrib>PETTERSSON, M</creatorcontrib><creatorcontrib>EDWARDS, I. R</creatorcontrib><creatorcontrib>SANDERSON, J. H</creatorcontrib><creatorcontrib>TAYLOR, N. F. A</creatorcontrib><creatorcontrib>FLETCHER, A. P</creatorcontrib><creatorcontrib>SCHOU, J. S</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>European journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>STAHL, M. M. S</au><au>LINDQUIST, M</au><au>PETTERSSON, M</au><au>EDWARDS, I. R</au><au>SANDERSON, J. H</au><au>TAYLOR, N. F. A</au><au>FLETCHER, A. P</au><au>SCHOU, J. S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system</atitle><jtitle>European journal of clinical pharmacology</jtitle><addtitle>Eur J Clin Pharmacol</addtitle><date>1997</date><risdate>1997</risdate><volume>53</volume><issue>3-4</issue><spage>163</spage><epage>169</epage><pages>163-169</pages><issn>0031-6970</issn><eissn>1432-1041</eissn><abstract>The present study was performed both to investigate whether there might be a difference between the selective serotonin re-uptake inhibitors, (SSRIs) with regard to the incidence of withdrawal reactions, and to describe the associated symptoms. From the WHO database, therefore, all case reports from the year of introduction for each of the SSRIs, fluoxetine, paroxetine and sertraline, were retrieved. Sales figures were obtained from Intercontinental Medical Statistics International. The reporting rates were calculated as the number of reports per million defined daily doses (DDDs) sold per year.
The reporting rate of withdrawal reactions for paroxetine was found to be higher than that for sertraline and fluoxetine in each of the countries selected for detailed analyses (US, UK and Australia), as well as for all 16 countries combined. Moreover, using the WHO system of organ classification, the ratio of central nervous system to psychiatric withdrawal symptoms was 1.9 and 2.1 for paroxetine and sertraline, respectively, whereas that for fluoxetine was 0.48, indicating a possible qualitative difference between the SSRIs with respect to the nature of the withdrawal syndrome.</abstract><cop>Heidelberg</cop><cop>Berlin</cop><pub>Springer</pub><pmid>9476026</pmid><doi>10.1007/s002280050357</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-6970 |
| ispartof | European journal of clinical pharmacology, 1997, Vol.53 (3-4), p.163-169 |
| issn | 0031-6970 1432-1041 |
| language | eng |
| recordid | cdi_proquest_journals_1530424151 |
| source | MEDLINE; SpringerLink Journals |
| subjects | 1-Naphthylamine - adverse effects 1-Naphthylamine - analogs & derivatives Adverse Drug Reaction Reporting Systems Antidepressants Biological and medical sciences Drug toxicity and drugs side effects treatment Female Fluoxetine - adverse effects Humans Male Medical sciences Paroxetine - adverse effects Pharmacology. Drug treatments Serotonin Uptake Inhibitors - adverse effects Sertraline Substance Withdrawal Syndrome Toxicity: nervous system and muscle World Health Organization |
| title | Withdrawal reactions with selective serotonin re-uptake inhibitors as reported to the WHO system |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A33%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Withdrawal%20reactions%20with%20selective%20serotonin%20re-uptake%20inhibitors%20as%20reported%20to%20the%20WHO%20system&rft.jtitle=European%20journal%20of%20clinical%20pharmacology&rft.au=STAHL,%20M.%20M.%20S&rft.date=1997&rft.volume=53&rft.issue=3-4&rft.spage=163&rft.epage=169&rft.pages=163-169&rft.issn=0031-6970&rft.eissn=1432-1041&rft_id=info:doi/10.1007/s002280050357&rft_dat=%3Cproquest_cross%3E3319868101%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1530424151&rft_id=info:pmid/9476026&rfr_iscdi=true |